RXST
RxSight, Inc. · Healthcare · Medical - Devices
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2026
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 1 | 0 | 31.92K | $154,807 | n/a | n/a |
| Q2 2026 | 70 | -7 | 30.76M | $148.37M | +3 | −9 |
| Q1 2026 | 78 | +10 | 29.02M | $178.70M | +11 | −1 |
| Q4 2025 | 68 | 0 | 28.07M | $292.47M | +1 | −1 |
| Q3 2025 | 17 | 0 | 14.88M | $133.76M | +1 | −1 |
| Q2 2025 | 14 | 0 | 12.67M | $164.75M | +1 | −1 |
| Q1 2025 | 11 | -1 | 4.08M | $103.15M | n/a | −1 |
| Q4 2024 | 12 | 0 | 5.10M | $175.38M | n/a | n/a |
| Q3 2024 | 11 | -1 | 3.15M | $155.64M | n/a | −1 |
| Q2 2024 | 12 | n/a | 2.73M | $164.29M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Wealth Enhancement Advisory… | 31.92K | -25.0% | $154,807 | 0.0% | ▼ Trim | 3 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 162 holders, 37.72M shares, $223.80M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 2.04K sh · $14,205
Officer · 5.10K sh · $35,496
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology